Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Search
Advanced search
OR
Browse
Search
Volume 20, Issue 1
Displaying 1-7 of 7 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
  • The role of DDS to overcome resistance
    Shigeru Kohno
    2005 Volume 20 Issue 1 Pages 9
    Published: January 10, 2005
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.20.9
    JOURNAL FREE ACCESS
    Download PDF (192K)
  • The role of DDS to overcome resistance
    DDS in cancer chemotherapy
    Shuji Takahashi, Toshiharu Yamaguchi
    2005 Volume 20 Issue 1 Pages 22-29
    Published: January 10, 2005
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.20.22
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Various drug delivery systems(DDS) have been developed in order to improve pharmacokinetics of anti-cancer drugs and to target them to tumor tissues, then to decrease toxicity and increase efficacy of cancer chemotherapy. DDS drugs approved for clinical practice include: (1) liposomal drugs such as liposomal doxorubicin, (2) polymer drugs such as SMANCS, (3) antibody conjugates such as CD33 Ab-calicheamicin, (4) ligand fusion proteins such as diphtheria toxin-IL-2. In this paper, efficacy and side effects of those drugs are reviewed.
    View full abstract
    Download PDF (1890K)
  • The role of DDS to overcome resistance
    DDS in development of anticancer agent
    Yasuhiro Matsumura
    2005 Volume 20 Issue 1 Pages 30-34
    Published: January 10, 2005
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.20.30
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The various mechanism of anticancer drug resistance is well known. Currently published data, however, do not yet show that MDR reversal agents will be useful clinically. In the present study, polymer micelle-based or immunoliposome-based drug delivery system also could not overcome multidrug-resistance. There is a natural drug resistance in solid tumors in terms of drug delivery: sufficient drug delivery can not be achieved in cancers having very few tumor vessels and an abundant collagen-rich interstitium. Such cancers include scinhous stomach cancer, inflammatory breast cancer, and pancreatic cancer. It is described how to cope with the natural drug resistance in this paper.
    View full abstract
    Download PDF (1049K)
  • The role of DDS to overcome resistance
    Intracellular targeting by transferrin-PEG pendant type liposomes, for boron neutron-capture therapy (BNCT)
    Kazuo Maruyama
    2005 Volume 20 Issue 1 Pages 35-41
    Published: January 10, 2005
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.20.35
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The successful treatment of cancer by BNCT requires the selective delivery of relatively high concentration of 10B compounds to malignant tumor tissue. When TF-PEG liposomes were injected, we observed a prolonged residence time in the circulation and low uptake by the RES in colon26 tumor-bearing mice, resulting in enhanced accumulation of 10B into the solid tumor tissue. TF-PEG liposomes maintained a high 10B level in the tumor for at least 72 hours after injection. Intravenous injection of TF-PEG liposomes can increase the tumor retention of 10B atoms, which were introduced by receptor-mediated endocytosis of liposomes after binding, causing tumor growth suppression in vivo upon thermal neutron irradiation. These results suggest that BSI-I-encapsulating TF-PEG liposomes could be useful as a new intracellular targeting carrier in BNCT therapy for cancer.
    View full abstract
    Download PDF (1442K)
  • The role of DDS to overcome resistance
    Development of cell delivery system for optimal cancer immunotherapy
    Toshiki Sugita, Jian-Qing Gao, Shinsaku Nakagawa
    2005 Volume 20 Issue 1 Pages 42-48
    Published: January 10, 2005
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.20.42
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The immune cells such as cytotoxic T lymphocytes, NK cells, and antigen presenting cells play a central role in cancer immunotherapy. These effector cells can be used as “drugs” for cancer therapy from the view of drug delivery system (DDS). We anticipated that optimal cancer immunotherapy can be achieved by controlling of the distribution of these so-called “live drugs” in the body. In the present study, we focus on a cell delivery system which can potentially control the systemic pharmacokinetics of immune cells and especially focus on the cell migrating molecule, chemokine and its receptor, as well as its use in cancer immunotherapy.
    View full abstract
    Download PDF (1530K)
  • The role of DDS to overcome resistance
    Gene delivery system for multidrug-resistance
    Shigeru Kawakami, Mitsuru Hashida
    2005 Volume 20 Issue 1 Pages 49-54
    Published: January 10, 2005
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.20.49
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Multidrug resistance (MDR) is a major obstacle in cancer chemotherapy. In order to overcome the MDR, pharmacologically active compounds, designated MDR modulators or chemosensitizers, may circumvent the “classical” MDR phenotype by inhibiting the efflux pump activity of P-glycoprotein. One obstacle in applying MDR modulators arises from their commonly occurring intrinsic toxicity at doses necessary to be active, e.g. hear failure, hypotension, hyperbilirubinemia, and immunosupression. Additionally, tumor cells can develop resistance against the applied chemosensitizers, so-called tertiary resistance. Consequently, it is necessary to develo palternative, less toxic and more efficient strategies to overcome MDR. Such an alternative procedure to circumvent P-glycoprotein mediated MDR in cancer cells is to prevent the biosynthesis of P-glycoprotein by selective blocking the expression the MDRI mRNA. In this article, we shall focus on the progress of novel gene therapy system against the MDR.
    View full abstract
    Download PDF (1383K)
  • The role of DDS to overcome resistance
    DDS against infectious diseases with resistant bacteria
    Katsunori Yanagihara, Shigeru Kohno
    2005 Volume 20 Issue 1 Pages 55-60
    Published: January 10, 2005
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.20.55
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Recently, resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or penicillin-resistant Streptococcus pneunioniae(PRSP) is widely prevalent. Thus, the new treatment rather than antimicrobial agents has been needed. The gene therapy that expresses inflammatory cytokines is currently under development. The transient transgenic expression of IFN-γ or TNF-α may be of potential therapeutic benefit in bacterial infection. Several investigators have suggested the efficacy of antisense nucleotide against Influenza virus. RNA interference(RNAi) is a process by which double-stranded RNA (dsRNA)directs sequence-specific degradation of messenger RNA (mRNA). The usefulness of RNAi against severe acute respiratory syndrome(SARS) virus is recently reported. Short-interfering RNA may be a new strategy against infectious diseasesin the near future.
    View full abstract
    Download PDF (1121K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top